Esperion to Report Second Quarter 2023 Financial Results on August 1
July 17 2023 - 6:00AM
Esperion (NASDAQ: ESPR), today announced it will report second
quarter 2023 financial results before the market opens on Tuesday,
August 1, 2023.
Following the release, management will host a
webcast at 8:00 a.m. ET to discuss these financial results and
provide business updates. Please click here to pre-register to
participate in the conference call and obtain your dial in number
and PIN.
Already registered? Access with your PIN
here.
A live audio webcast can be accessed on the
investor and media section of the Esperion website at
investor.esperion.com. Access to the webcast replay will be
available approximately two hours after completion of the call and
will be archived on the Company's website for approximately 90
days.
Esperion TherapeuticsAt
Esperion, we discover, develop, and commercialize innovative
medicines to help improve outcomes for patients with or at risk for
cardiovascular and cardiometabolic diseases. The status quo is not
meeting the health needs of millions of people with high
cholesterol – that is why our team of passionate industry leaders
is breaking through the barriers that prevent patients from
reaching their goals. Providers are moving toward reducing
LDL-cholesterol levels as low as possible, as soon as possible; we
provide the next steps to help get patients there. Because when it
comes to high cholesterol, getting to goal is not optional. It is
our life’s work. For more information, visit esperion.com and
esperionscience.com and follow us on Twitter at
twitter.com/EsperionInc.
Esperion Contact Information:
Investors: Alexis Callahaninvestorelations@esperion.com (406)
539-1762 Media: Tiffany Aldrich
corporateteam@esperion.com (616) 443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024